STOCK TITAN

Kiniksa (KNSA) director Quart exercises options, sells 13,099 shares under 10b5-1 plan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc director Barry D. Quart executed an option exercise-and-sale transaction in Class A Ordinary Shares. He exercised options to acquire 13,099 shares at $14.33 per share and sold 13,099 shares at a weighted average price of $50.10 under a pre-arranged Rule 10b5-1 plan. The sale occurred in multiple broker-dealer trades between $50.00 and $50.725. After these transactions, he directly holds 12,546 shares and 13,237 remaining share options that are fully vested and exercisable, expiring on June 28, 2031.

Positive

  • None.

Negative

  • None.

Insights

Routine 10b5-1 option exercise and sale with modest net share reduction.

Director Barry D. Quart exercised options for 13,099 Class A Ordinary Shares at $14.33 and sold the same number at a weighted average of $50.10. The pattern reflects an exercise-and-sell sequence rather than a fresh open-market purchase.

The filing shows this sale was effected under a pre-established Rule 10b5-1 plan dated September 11, 2025, suggesting a pre-planned liquidity event instead of discretionary timing. Following the transactions, Quart still holds 12,546 shares and 13,237 vested options expiring on June 28, 2031.

Insider Quart Barry D
Role null
Sold 13,099 shs ($656K)
Type Security Shares Price Value
Exercise Share Option 13,099 $0.00 --
Exercise Class A Ordinary Share 13,099 $14.33 $188K
Sale Class A Ordinary Share 13,099 $50.10 $656K
Holdings After Transaction: Share Option — 13,237 shares (Direct, null); Class A Ordinary Share — 25,645 shares (Direct, null)
Footnotes (1)
  1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $50.00 and $50.725. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. The option is fully vested and exercisable.
Shares sold 13,099 shares Class A Ordinary Shares sold in open market on April 28, 2026
Weighted average sale price $50.10 per share Open-market sales between $50.00 and $50.725
Option exercise price $14.33 per share Share Option for 13,099 underlying Class A Ordinary Shares
Shares held after transaction 12,546 shares Direct Class A Ordinary Share holdings following transactions
Options remaining 13,237 options Fully vested share options expiring June 28, 2031
Rule 10b5-1 plan regulatory
"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average sales price financial
"The price reported in this column reflects a weighted average sales price"
Class A Ordinary Share financial
"security_title: Class A Ordinary Share"
A Class A ordinary share is a type of common stock a company issues that carries a specific set of rights—most often particular voting power, dividend terms, or transfer rules—distinct from other share classes. For investors it matters because those rights affect control over company decisions, how income is paid out, and how easy shares are to buy or sell; think of it like a tiered ticket that gives different access and influence at the same event.
Share Option financial
"security_title: Share Option"
exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Quart Barry D

(Last)(First)(Middle)
C/O KINIKSA PHARMACEUTICALS INT'L
105 PICCADILLY, SECOND FLOOR

(Street)
LONDONW1J 7NJ

(City)(State)(Zip)

UNITED KINGDOM

(Country)
2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/28/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Ordinary Share04/28/2026M(1)13,099A$14.3325,645D
Class A Ordinary Share04/28/2026S(1)13,099D$50.1(2)12,546D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Share Option$14.3304/28/2026M(1)13,099 (3)06/28/2031Class A Ordinary Shares13,099$013,237D
Explanation of Responses:
1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025.
2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $50.00 and $50.725. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
3. The option is fully vested and exercisable.
/s/ Douglas Barry, Attorney-in-Fact04/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Kiniksa (KNSA) director Barry D. Quart do in this Form 4 filing?

Barry D. Quart exercised options for 13,099 Class A Ordinary Shares and sold 13,099 shares in the open market. The transactions form an exercise-and-sell pattern, converting option value into cash while leaving him with remaining share and option holdings.

At what prices did Barry D. Quart sell Kiniksa (KNSA) shares?

Quart sold 13,099 Class A Ordinary Shares at a weighted average price of $50.10 per share. Footnotes state individual trades were executed through a broker between $50.00 and $50.725, with full trade details available from him upon request.

How many Kiniksa (KNSA) shares and options does Barry D. Quart hold after these transactions?

After the reported transactions, Quart directly holds 12,546 Class A Ordinary Shares. He also retains 13,237 fully vested share options, which are exercisable and scheduled to expire on June 28, 2031, providing continued equity exposure.

Were Barry D. Quart’s Kiniksa (KNSA) share sales made under a Rule 10b5-1 plan?

Yes. A footnote explains the share sale was effected pursuant to a Rule 10b5-1 trading plan executed on September 11, 2025. Such pre-arranged plans automate trades and generally indicate routine portfolio management rather than discretionary market timing.

What type of option did Barry D. Quart exercise in Kiniksa (KNSA)?

Quart exercised a Share Option covering 13,099 underlying Class A Ordinary Shares at a conversion price of $14.33 per share. The option is fully vested and exercisable, with the remaining option position expiring on June 28, 2031 according to the filing.